GeminIQ Website Logo

Viewing BGLC free

Start free trial

Subscribe for full history, 90+ metrics, screener, watchlist...

BioNexus Gene Lab Corp

BGLC

Companies in Services-Medical Laboratories

NTRADGXLHGHCELCBLLN

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Cash
--------2350
Liabilities And Stockhold…
Cash Equivalents At Carrying Value
----1222-3--
Deposits Assets
----33233311
Cash And Cash Equivalents At Carrying Value
1211-2------
Deposits Assets Current
3222-3------
Assets Current
Accounts Receivable Net Current
0122-1------
Assets Current
556677788885
Accounts Receivable Net
-1--11111112
Other Receivables Net Current
000000000000
Assets Noncurrent
Assets Noncurrent
442333433333
Other Assets Current
00---0------
Income Taxes Receivable
000000000000
Inventory Net
111111111111
Operating Lease Right Of Use Asset
000000000000
Finance Lease Right Of Use Asset
0-----------
Property Plant And Equipment Net
222222211211
Other Investments
------222221
Equity Securities Fv Ni Current And Noncurrent
----11---2--
Equity Method Investments
2201-1------
Assets
998991011111111118
Accounts Payable Current
----12111122
Accounts Payable Trade Current
0001-2------
Other Accounts Payable And Accrued Liabilities
100000000000
Operating Lease Liability Current
000000000000
Liabilities Current
Liabilities Current
111222112222
Finance Lease Liability Current
0-----------
Customer Advances Current
00000000-000
Taxes Payable Current
----------0-
Operating Lease Liability Noncurrent
000000000000
Liabilities Noncurrent
Liabilities Noncurrent
000000000000
Deferred Income Tax Liabilities Net
--0000000000
Finance Lease Liability Noncurrent
0-----------
Liabilities
111222222222
Common Stock Value
202017171717171717171711
Additional Paid In Capital
-5-5-5-5-5-5-5-5-5-5-5-5
Stockholders Equity
Stockholders Equity
89788891091096
Retained Earnings Accumulated Deficit
-7-6-5-5-4-3-3-2-2-2-21
Accumulated Other Comprehensive Income Loss Net Of…
-0-0-0-0-0-1-0-1-1-1-1-1
Liabilities And Stockholders Equity
998991011111111118
Common Stock Par Or Stated Value Per Share
000000000000
Common Stock Shares Authorized
300300300300300300300300300300300300
Shares Outstanding
22221821818181818174
Preferred Stock Par Or Stated Value Per Share
000000000000
Preferred Stock Shares Authorized
303030303030303030303030
Preferred Stock Shares Outstanding
000000000000
Deposit Assets
222221---1--
Allowance For Doubtful Accounts Receivable Current
111011---1--
Other Inventory In Transit
-000-0---0--

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
20268.96%0.54%-34.62%---------
20251.97%111.51%112.83%2.07%-2.44%-4.32%-9.27%-13.02%-42.67%-5.07%1.38%-6.45%
2024-4.14%-20.00%-17.59%-7.24%-4.52%-14.71%-3.00%53.67%36.00%0.75%16.98%142.64%
2023---58.33%-2.22%-43.19%-14.04%-17.77%-36.68%-7.94%-11.75%-26.35%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
6.52
10.46
8.30
3.63
4.19
3.81
4.98
5.60
4.61
4.93
5.03
2.79
Quick Ratio
5.69
9.16
6.81
2.94
3.44
3.10
3.99
4.87
3.98
4.24
4.36
2.16
Working Capital
4.40M
4.93M
4.95M
4.62M
4.98M
5.48M
5.62M
6.44M
6.19M
6.42M
6.63M
3.35M
Leverage & Debt
Debt to Equity
0.12
0.07
0.12
0.25
0.22
0.25
0.17
0.17
0.19
0.18
0.19
0.35
Interest Coverage TTM
-
-
-
-481.76
-263.25
-146.55
-70.18
-192.03
-228.28
-231.16
-325.49
-104.70
Debt Ratio
0.10
0.07
0.11
0.20
0.18
0.20
0.15
0.14
0.16
0.15
0.16
0.24
Efficiency & Turnover
Asset Turnover TTM
0.57
0.75
1.02
0.93
0.90
0.87
0.82
0.96
1.01
0.97
1.07
1.27
Days Sales Outstanding TTM
5.49
46.27
58.70
70.77
-
52.83
-
-
-
-
-
-
Receivables Turnover TTM
66.50
7.89
6.22
5.16
-
6.91
-
-
-
-
-
-
Per Share Metrics
Diluted EPS TTM
-1.20
-
-1.28
-1.63
-1.18
-0.09
-0.52
-1.25
-0.15
-0.17
-
-
Free Cash Flow Per Share TTM
-0.49
-0.78
-1.46
-1.77
-0.17
-1.29
-0.18
-0.14
-0.11
-0.11
-0.04
0.00
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Margin Metrics
Gross Profit Margin TTM
13.95%
14.62%
14.77%
14.11%
13.68%
13.56%
13.47%
13.88%
13.56%
13.61%
13.56%
13.01%
Operating Profit Margin TTM
-54.36%
-39.93%
-24.81%
-31.24%
-22.81%
-16.55%
-9.72%
-22.77%
-26.82%
-26.54%
-28.77%
-4.93%
Net Profit Margin TTM
-54.70%
-40.20%
-24.27%
-30.71%
-22.86%
-16.81%
-10.17%
-24.02%
-27.25%
-26.91%
-29.94%
-5.43%
Growth Metrics
Net Revenue Growth (1Y)
-42.69%
-21.93%
2.22%
4.01%
-5.21%
-2.66%
-10.42%
-11.35%
-4.88%
-10.60%
-8.80%
-16.02%
Net Income Growth (1Y)
37.16%
86.73%
143.94%
33.00%
-20.49%
-39.20%
-69.57%
291.94%
502.52%
638.57%
2,719.46%
-313.97%
EPS Growth (1Y)
919.47%
38.80%
2,339.60%
1,207.93%
-21.82%
497.81%
-69.87%
3,753.74%
5,824.32%
505.17%
27,427.76%
-310.90%
Valuation Metrics
P/E TTM
-1.78
-3.20
-4.28
-1.88
-20.02
-3.15
-84.92
-38.05
-46.83
-35.62
-50.02
-8,187.51
P/B TTM
0.64
1.11
1.44
0.73
5.46
0.60
8.52
8.79
13.35
9.70
16.62
823.84
P/S TTM
0.97
1.29
1.04
0.58
4.58
0.53
8.63
9.14
12.76
9.58
14.97
444.75
Market Cap
5.18M
9.55M
9.83M
5.52M
42.40M
5.03M
79.96M
83.92M
124.73M
93.64M
154.80M
4.61B
Enterprise Value
3.89M
7.17M
8.67M
4.70M
40.31M
3.45M
75.82M
78.51M
120.30M
89.12M
148.65M
4.61B
Calculated Values
Free Cash Flow TTM
-1.19M
-1.88M
-2.62M
-3.18M
-3.09M
-2.32M
-3.32M
-2.55M
-1.91M
-1.97M
-748.55K
590.03K
Net Debt
-1.28M
-2.38M
-1.15M
-814.18K
-2.09M
-1.58M
-4.14M
-5.41M
-4.44M
-4.52M
-6.15M
-1.76M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Start free trial
No insider data available.

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart
2026-03-31
0.01%
Inst. Shares: 232
Shares Outstanding: 2,417,314
2025-12-31
1.98%
Inst. Shares: 47,830
Shares Outstanding: 2,417,314
2025-09-30
1.24%
Inst. Shares: 22,277
Shares Outstanding: 1,796,597
2025-06-30
0.53%
Inst. Shares: 9,562
Shares Outstanding: 1,796,597
2025-03-31
0.88%
Inst. Shares: 157,985
Shares Outstanding: 17,967,663

BioNexus Gene Lab Corp (BGLC) — SEC Financial Statements & Analysis

BioNexus Gene Lab Corp (BGLC) is a services-medical laboratories company, incorporated in WY. BioNexus Gene Lab Corp trades on Nasdaq as: BGLC. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), BioNexus Gene Lab Corp reported a -42.69% year-over-year revenue growth, a Gross Profit Margin of 13.95% (TTM), a Debt-to-Equity ratio of 0.12x, a Price-to-Sales (P/S) ratio of 0.97x (TTM), a Price-to-Book (P/B) ratio of 0.64 (TTM), at a market cap of $5.18M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y
-42.69%
Gross Profit Margin TTM
13.95%
Debt To Equity
0.12x
P/S TTM
0.97x
P/B TTM
0.64
Market Cap
$5.18M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BioNexus Gene Lab Corp in?

BioNexus Gene Lab Corp (BGLC) operates in the Services-Medical Laboratories industry.

What is BGLC's market cap?

BioNexus Gene Lab Corp (BGLC) has a market capitalization of $5.18M as of 2026-03-31.

What exchange does BGLC trade on?

BioNexus Gene Lab Corp (BGLC) trades on the Nasdaq.

Where is BioNexus Gene Lab Corp incorporated?

BioNexus Gene Lab Corp is incorporated in WY.

Research Faster.
Invest Smarter.

Start 7-day free trial

BioNexus Gene Lab Corp (BGLC) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 90+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.